JP2013533213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533213A5 JP2013533213A5 JP2013510362A JP2013510362A JP2013533213A5 JP 2013533213 A5 JP2013533213 A5 JP 2013533213A5 JP 2013510362 A JP2013510362 A JP 2013510362A JP 2013510362 A JP2013510362 A JP 2013510362A JP 2013533213 A5 JP2013533213 A5 JP 2013533213A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- agent
- pharmaceutical composition
- cell
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33499110P | 2010-05-14 | 2010-05-14 | |
| US61/334,991 | 2010-05-14 | ||
| US37074510P | 2010-08-04 | 2010-08-04 | |
| US61/370,745 | 2010-08-04 | ||
| US37586310P | 2010-08-22 | 2010-08-22 | |
| US61/375,863 | 2010-08-22 | ||
| US201161467342P | 2011-03-24 | 2011-03-24 | |
| US201161467376P | 2011-03-24 | 2011-03-24 | |
| US61/467,342 | 2011-03-24 | ||
| US61/467,376 | 2011-03-24 | ||
| PCT/US2011/036672 WO2011143660A2 (en) | 2010-05-14 | 2011-05-16 | Compositions and methods for treating leukemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208118A Division JP2016102105A (ja) | 2010-05-14 | 2015-10-22 | 白血病を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533213A JP2013533213A (ja) | 2013-08-22 |
| JP2013533213A5 true JP2013533213A5 (https=) | 2014-07-03 |
| JP5935030B2 JP5935030B2 (ja) | 2016-06-15 |
Family
ID=44915025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510362A Active JP5935030B2 (ja) | 2010-05-14 | 2011-05-16 | 白血病を治療するための組成物および方法 |
| JP2015208118A Pending JP2016102105A (ja) | 2010-05-14 | 2015-10-22 | 白血病を治療するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208118A Pending JP2016102105A (ja) | 2010-05-14 | 2015-10-22 | 白血病を治療するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9815849B2 (https=) |
| EP (1) | EP2569434B1 (https=) |
| JP (2) | JP5935030B2 (https=) |
| CN (2) | CN103154246B (https=) |
| AU (1) | AU2011252799B2 (https=) |
| BR (1) | BR112012029057A2 (https=) |
| CA (1) | CA2799403C (https=) |
| MX (2) | MX354217B (https=) |
| WO (1) | WO2011143660A2 (https=) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| EP2571875A4 (en) | 2010-05-14 | 2013-10-30 | Dana Farber Cancer Inst Inc | CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| CN103119160B (zh) * | 2010-05-14 | 2016-06-01 | 达那-法伯癌症研究所 | 用于调节代谢的组合物和方法 |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
| EP2861255B1 (en) | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| CA2896053A1 (en) | 2012-12-21 | 2014-06-26 | Ocata Therapeutics, Inc. | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| CN106029077A (zh) | 2013-08-01 | 2016-10-12 | 翁科埃斯克斯有限公司 | 包含噻吩并三唑并二氮杂卓化合物的药物制剂 |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| CN105960239A (zh) | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| WO2015120476A1 (en) * | 2014-02-10 | 2015-08-13 | Salk Institute For Biological Studies | Increasing storage of vitamin a, vitamin d and/or lipids |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
| WO2015131005A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| WO2015144636A1 (en) | 2014-03-24 | 2015-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of t-cell acute lymphoblastic leukemias |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
| EP3137085A4 (en) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
| PL3157928T3 (pl) | 2014-06-20 | 2019-07-31 | Constellation Pharmaceuticals, Inc. | Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu |
| CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| CN106793775B (zh) | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | 二氢碟啶酮衍生物及其用途 |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US20170281642A1 (en) * | 2014-08-28 | 2017-10-05 | Oncoethix Gmbh | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
| TWI716367B (zh) * | 2014-10-31 | 2021-01-21 | 麻省理工學院 | 用於常間回文重複序列叢集（ｃｒｉｓｐｒ）之大量平行組合性基因學 |
| EP3262045A1 (en) | 2015-02-27 | 2018-01-03 | The Regents of The University of Michigan | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| HK1251655A1 (zh) | 2015-04-20 | 2019-02-01 | Tolero Pharmaceuticals, Inc. | 通过线粒体分析预测对阿伏西地的应答 |
| KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
| WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| JP7083497B2 (ja) | 2015-08-03 | 2022-06-13 | スミトモ ファーマ オンコロジー， インコーポレイテッド | がんの処置のための併用療法 |
| BR112018002550A2 (en) | 2015-08-10 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | inhibitor resistance mechanism |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| EP3347021A4 (en) | 2015-09-11 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| US11548899B2 (en) | 2016-02-15 | 2023-01-10 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors |
| EP3426781B1 (en) * | 2016-03-07 | 2024-06-26 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Micrornas and methods of their use |
| US10517877B2 (en) | 2016-03-30 | 2019-12-31 | Wisconsin Alumni Research Foundation | Compounds and methods for modulating frataxin expression |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| KR20180132861A (ko) | 2016-04-12 | 2018-12-12 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bet 단백질 분해제 |
| CA3028689A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| JP2018014972A (ja) * | 2016-07-29 | 2018-02-01 | 国立大学法人大阪大学 | 未分化細胞が除去された分化誘導細胞集団の製造方法 |
| CA3036841A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet protein degraders |
| CA3036834A1 (en) | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CA3041949A1 (en) | 2016-12-16 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for the manufacture of diazepine derivatives |
| AU2017379847B2 (en) * | 2016-12-19 | 2022-05-26 | Sumitomo Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2018144789A1 (en) | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
| US11759533B2 (en) | 2017-03-29 | 2023-09-19 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating gene expression |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| WO2019055444A1 (en) | 2017-09-13 | 2019-03-21 | The Regents Of The University Of Michigan | DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| AU2019284971A1 (en) | 2018-06-13 | 2020-12-03 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | Preparation of condensed triazepine derivatives and their use as BET inhibitors |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| WO2021074338A1 (en) * | 2019-10-16 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy |
| CN115135765A (zh) * | 2019-11-08 | 2022-09-30 | 菲奥医药公司 | 用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸 |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| KR20230023612A (ko) | 2020-04-02 | 2023-02-17 | 마이레큘, 인크. | 조작된 올리고뉴클레오티드를 사용한 표적화된 억제 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US20240316061A1 (en) | 2021-09-17 | 2024-09-26 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| CN117169489B (zh) * | 2023-07-18 | 2024-09-10 | 西湖实验室(生命科学和生物医学浙江省实验室) | 一种用于处理生物样品以鉴定其中蛋白质的方法 |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3709898A (en) | 1971-02-09 | 1973-01-09 | Upjohn Co | Process for the production of triazolobenzodiazepines and intermediates |
| US3681343A (en) | 1971-05-11 | 1972-08-01 | Upjohn Co | 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines |
| US3812259A (en) | 1971-08-09 | 1974-05-21 | Upjohn Co | Animal feed and process |
| CH622019A5 (en) | 1975-10-23 | 1981-03-13 | Upjohn Co | Process for the preparation of aminotriazolobenzodiazepines |
| FR2329668A1 (fr) | 1975-10-27 | 1977-05-27 | Upjohn Co | Procede de preparation d'aminotriazolobenzodiazepines |
| EP0087850A1 (en) | 1982-01-04 | 1983-09-07 | The Upjohn Company | Benzodiazepines for anti-hypertensive use |
| DE3435973A1 (de) | 1984-10-01 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung |
| DE3724164A1 (de) | 1986-07-25 | 1988-01-28 | Boehringer Ingelheim Kg | Neue 1,4-benzodiazepine, ihre herstellung und verwendung |
| EP0315698B1 (en) | 1987-05-28 | 1993-03-03 | Yoshitomi Pharmaceutical Industries, Ltd. | Thieno(triazolo)diazepine compounds and medicinal application of the same |
| JPH0676326B2 (ja) | 1988-05-24 | 1994-09-28 | 吉富製薬株式会社 | 循環器系疾患治療薬 |
| EP0368175A1 (de) | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin. |
| EP0387613A1 (de) | 1989-03-03 | 1990-09-19 | Boehringer Ingelheim Kg | Neue Thienodiazepine |
| YU133090A (sh) | 1989-07-12 | 1993-10-20 | Boehringer Ingelheim Kg. | Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| EP0638560A4 (en) | 1991-10-11 | 1995-03-29 | Yoshitomi Pharmaceutical | MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *. |
| WO1994006802A1 (fr) | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
| EP0692483A1 (en) | 1993-03-30 | 1996-01-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Cell adhesion inhibitor and thienotriazolodiazepine compound |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| EP1179340A3 (en) | 1994-09-30 | 2003-05-07 | INEX Pharmaceutical Corp. | Compositions for the introduction of polyanionic materials into cells |
| US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
| US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
| US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
| DK0801651T3 (da) | 1995-01-06 | 2001-10-22 | Hoffmann La Roche | Hydroxymethyl-imidazodiazepiner og deres estere |
| BR9610390A (pt) | 1995-09-09 | 1999-07-06 | Hoffmann La Roche | O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i |
| CA2258053A1 (en) | 1996-06-12 | 1997-12-18 | Yoshihisa Yamamoto | Cytokine production inhibitors, triazepine compounds, and intermediates thereof |
| CN1109037C (zh) | 1996-09-13 | 2003-05-21 | 三菱制药株式会社 | 噻吩并－三唑并二氮杂䓬化合物及其医药用途 |
| US6444664B1 (en) | 1997-04-18 | 2002-09-03 | Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) | Method for controlling the plasma level of lipoproteins to treat alzheimeris disease |
| JP2002508765A (ja) | 1997-06-23 | 2002-03-19 | アルザ コーポレイション | リポソーム被包ポリヌクレオチド組成物および方法 |
| IE970794A1 (en) | 1997-09-24 | 2000-08-23 | Elan Corp Plc | Composition and method for enhancing paracellular transport across cell layers |
| JPH11228576A (ja) | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| KR20000016732A (en) | 1998-12-12 | 2000-03-25 | Japan Tobacco Inc | Cytokine production inhibitors, triazepine compounds, and intermediates thereof |
| CZ20014083A3 (cs) | 1999-05-14 | 2002-08-14 | Imclone Systems Incorporated | Léčivo pro indikaci růstu refrakterních nádorů |
| US7589167B2 (en) | 2000-02-22 | 2009-09-15 | J. David Gladstone Institutes | ZA loops of bromodomains |
| WO2001095912A1 (fr) | 2000-06-16 | 2001-12-20 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
| WO2002002557A2 (en) | 2000-06-30 | 2002-01-10 | Neurogen Corporation | 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands |
| US20060142257A1 (en) | 2001-01-19 | 2006-06-29 | Eberhard Nieschlag | Male contraceptive formulation comprising norethisterone |
| US6979682B2 (en) * | 2001-02-23 | 2005-12-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast |
| US20030216758A1 (en) | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| CA2499188A1 (en) | 2002-09-27 | 2004-04-08 | Cold Spring Harbor Laboratory | Cell-based rna interference and related methods and compositions |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| CA2515790C (en) | 2003-02-27 | 2012-11-27 | Abbott Laboratories | Heterocyclic kinase inhibitors |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US20070111933A1 (en) | 2003-06-02 | 2007-05-17 | Kopchick John J | Diagnosis and treatment methods related to aging, especially of liver |
| WO2005002526A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Method and compositions for treatment of viral infections |
| US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| US20070105839A1 (en) | 2003-09-18 | 2007-05-10 | Patricia Imbach | 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| EP1528056A1 (en) | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| CN1759834B (zh) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| CA2617589A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US20070105887A1 (en) | 2005-11-04 | 2007-05-10 | Wyeth | Antineoplastic combinations of temsirolimus and sunitinib malate |
| EA200870117A1 (ru) * | 2005-12-23 | 2008-12-30 | Смитклайн Бичам Корпорейшн | Азаиндоловые ингибиторы аурора-киназ |
| JP4913157B2 (ja) | 2006-01-17 | 2012-04-11 | エフ．ホフマン−ラ ロシュ アーゲー | ＧＡＢＡレセプター経由でのアルツハイマー病の処置に有用なアリール−イソオキサゾール−４−イル−イミダゾ［１，２−ａ］ピリジン誘導体 |
| US7622463B2 (en) | 2006-02-14 | 2009-11-24 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
| US20070218135A1 (en) | 2006-03-14 | 2007-09-20 | Glenmark Pharmaceuticals Limited | Sustained release matrix pharmaceutical composition |
| BRPI0711174A2 (pt) | 2006-05-03 | 2011-08-23 | Novartis Ag | uso de compostos orgánicos |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| ES2405655T3 (es) * | 2006-12-26 | 2013-05-31 | Lantheus Medical Imaging, Inc. | N-[3-bromo-4-(3-[18F]fluoropropoxi)-bencil]-guanidina para la formación de imágenes de la inervación cardíaca |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| WO2008137081A1 (en) | 2007-05-02 | 2008-11-13 | The Trustees Of Columbia University In The City Of New York | Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives |
| KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
| CA2710118A1 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| US20110098288A1 (en) | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
| WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
| ES2448567T3 (es) | 2008-10-30 | 2014-03-14 | Circomed Llc | Derivados de la tienotriazoldiazepina activos en apo A |
| EP3828185B1 (en) | 2009-01-06 | 2024-11-20 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| CN102341394B (zh) | 2009-01-23 | 2015-04-15 | 武田药品工业株式会社 | 聚(adp-核糖)聚合酶(parp)抑制剂 |
| US8895526B2 (en) | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AU2010314395B2 (en) | 2009-11-05 | 2015-04-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP3050885B1 (en) | 2009-11-05 | 2017-10-18 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| JP5841548B2 (ja) | 2010-02-17 | 2016-01-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノン、その製造方法及び使用 |
| EP2571875A4 (en) | 2010-05-14 | 2013-10-30 | Dana Farber Cancer Inst Inc | CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| CN103119160B (zh) | 2010-05-14 | 2016-06-01 | 达那-法伯癌症研究所 | 用于调节代谢的组合物和方法 |
| JP5844358B2 (ja) | 2010-06-22 | 2016-01-13 | グラクソスミスクライン エルエルシー | ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| US20120014979A1 (en) | 2010-07-16 | 2012-01-19 | Alexander Dent | Use of bcl6 inhibitors for treating autoimmune diseases |
| TWI549955B (zh) | 2010-08-04 | 2016-09-21 | 達納 法柏癌症學院有限公司 | 治療腫瘤形成、發炎疾病及其他病症之組成物及方法 |
| DK2621282T3 (da) | 2010-09-28 | 2020-05-04 | Univ California | Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US20130004481A1 (en) | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| AU2012220620A1 (en) | 2011-02-23 | 2013-10-03 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| CA2864394C (en) | 2011-03-02 | 2021-10-19 | Jack Roth | A method of predicting a response to a tusc2 therapy |
| CA2843643A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| US10071129B2 (en) | 2011-08-30 | 2018-09-11 | Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. | Method for identifying bromodomain inhibitors |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013123521A1 (en) | 2012-02-17 | 2013-08-22 | Nexbio, Inc. | Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients |
| WO2013148197A1 (en) | 2012-03-28 | 2013-10-03 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
| EP2861255B1 (en) | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| JP2015531365A (ja) | 2012-09-28 | 2015-11-02 | オンコエシックス エスエー | チエノトリアゾロジアゼピン化合物を含む医薬製剤 |
| EP2917203B1 (en) | 2012-11-02 | 2019-04-03 | Dana-Farber Cancer Institute, Inc. | Method for identifying myc inhibitors |
| WO2014128111A1 (de) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituierte pyrrolo- und pyrazolo-diazepine |
| EP2958922A1 (de) | 2013-02-22 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen |
| JP2016510039A (ja) | 2013-02-28 | 2016-04-04 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法 |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| JP2016519672A (ja) | 2013-03-15 | 2016-07-07 | ジェネンテック， インコーポレイテッド | ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療 |
| EP3003312A1 (en) | 2013-05-28 | 2016-04-13 | Dana-Farber Cancer Institute, Inc. | Bet inhibition therapy for heart disease |
| US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| JP2016529246A (ja) | 2013-08-06 | 2016-09-23 | オンコエシックス ゲーエムベーハー | Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法 |
| WO2015023938A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Epigenetic regulators of frataxin |
| AU2014323526B2 (en) | 2013-09-19 | 2020-07-23 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
| MX2016004570A (es) | 2013-10-11 | 2016-09-08 | Genentech Inc | Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer. |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| WO2015081284A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| CN105940005A (zh) | 2014-01-31 | 2016-09-14 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
| KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
| AU2015358334A1 (en) | 2014-12-05 | 2017-06-08 | Dana-Farber Cancer Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| US20180193350A1 (en) | 2015-06-26 | 2018-07-12 | Tensha Therapeutics, Inc. | Treatment of nut midline carcinoma |
| EP3355922A2 (en) | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
-
2011
- 2011-05-16 MX MX2012013256A patent/MX354217B/es active IP Right Grant
- 2011-05-16 WO PCT/US2011/036672 patent/WO2011143660A2/en not_active Ceased
- 2011-05-16 BR BR112012029057-6A patent/BR112012029057A2/pt not_active Application Discontinuation
- 2011-05-16 CA CA2799403A patent/CA2799403C/en active Active
- 2011-05-16 MX MX2018001971A patent/MX373121B/es unknown
- 2011-05-16 CN CN201180033581.3A patent/CN103154246B/zh active Active
- 2011-05-16 EP EP11781413.7A patent/EP2569434B1/en active Active
- 2011-05-16 AU AU2011252799A patent/AU2011252799B2/en active Active
- 2011-05-16 CN CN201510660739.XA patent/CN105582014B/zh active Active
- 2011-05-16 JP JP2013510362A patent/JP5935030B2/ja active Active
-
2013
- 2013-07-03 US US13/934,843 patent/US9815849B2/en active Active
-
2015
- 2015-10-22 JP JP2015208118A patent/JP2016102105A/ja active Pending
-
2017
- 2017-10-17 US US15/786,249 patent/US10676484B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533213A5 (https=) | ||
| Ciuclan et al. | Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression | |
| BR112012024923A2 (pt) | "fosforamidatos de nucleosídeo, composição, comprimido, e seus usos" | |
| ME02589B (me) | 4-(8-metoksi-1-((1-metoksipropan-2-il)-2-(tetrahidro-2h-piran-4-il) -1 h-imidazo[ 4,5-c]hinolin-7-il)-3,5-dimetilizoksazol i njegova upotreba kao inhibitora bromodomena | |
| BR112013029862A2 (pt) | derivados de piridin-2 (1h)-ona úteis como medicamentos para o tratamento de distúrbios mieloproliferativos, rejeição a transplante, doenças imunomediadas e inflamatórias | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| RU2015151204A (ru) | Композиции и способы | |
| NI201100063A (es) | Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38. | |
| JP2009537552A5 (https=) | ||
| CL2007003742A1 (es) | Compuestos derivados heterociclicos, inhibidores de protein quinasas activadas por mitogenos; proceso de preparacion; composicion farmaceutica; articulo de manufactura; y uso para el tratamiento de enfermedades tales como trastornos hiperproliferativ | |
| JP2013504542A5 (https=) | ||
| IL264288B (en) | Methods and compositions for modulating apolipoprotein(a) expression | |
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| JP2011006480A5 (https=) | ||
| BR112015019754A2 (pt) | derivados de 2-((4-amino-3-(3-fluoro-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)metil)-3-(2-(trifluoro-metil)bezil)quinazolin-4(3h)-ona e seu uso como inibidores de fosfoinositídeo 3-quinase | |
| IL215467A (en) | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation | |
| JP2013542261A5 (https=) | ||
| ECSP10010428A (es) | Derivados de indazol | |
| TN2016000234A1 (en) | Tropomyosin-related kinase (trk) inhibitors. | |
| JP2015516378A5 (https=) | ||
| US11702443B2 (en) | Therapeutic agents and methods | |
| Kelly et al. | TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia | |
| MX339302B (es) | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. | |
| MD20140004A2 (en) | Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia |